stonks4u
Sign up free
DMAC logo

DMAC DiaMedica Therapeutics Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$6.68
-0.07 (-1.04%)

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 d…

Market Cap: $359.94Mwww.diamedica.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

75
5083117150
Aug 10Aug 13

Quote

Day Range
$6.58 – $6.79
52-Week Range
$5.14 – $10.42
Volume
$165.0K
Market Cap
$359.94M
50-Day Avg
$6.66
200-Day Avg
$7.19
Prev Close
$6.75
Open
$6.71

Valuation & Ratios

P/E Ratio
-11.37
EPS
$-0.70
P/B Ratio
6.66
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
11.81
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-58.4%
Return on Assets
-53.4%
FCF Yield
-7.8%
EV/EBITDA
-10.97

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-32.77M$-0.70
2024$0.00$-24.44M$-0.60
2023$0.00$-19.38M$-0.60
2022$0.00$-13.68M$-0.52
2021$0.00$-13.59M$-0.65

Social Signal Score

58
5d
58
4 mentions
—
30d
58
4 mentions
—
60d
58
4 mentions
—
90d
58
4 mentions
—
news: 4

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.20 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-0.19 vs $-0.20beat
  • Wed, May 6$-0.19 vs $-0.17miss
  • Mon, Mar 30$-0.17 vs $-0.17beat
  • Wed, Nov 12$-0.17 vs $-0.15miss
  • Tue, Aug 12$-0.18 vs $-0.18beat
  • Tue, May 13$-0.18 vs $-0.18beat

Estimates and results for DMAC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

DMAChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (4)

  • Newszacks.com·2d ago·Positive

    All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    View source ↗
  • Newsseekingalpha.com·4d ago·Positive

    DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·4d ago·Negative

    DiaMedica Therapeutics Q2 Earnings Call Highlights DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027.

    View source ↗
  • Newsbusinesswire.com·4d ago·Neutral

    DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2026. Management will host a conference call Tuesday, August 11, 2026,

    View source ↗